Dr Patrick Vallance
Senior Vice President, Medicines Discovery & Development
Patrick was appointed Senior Vice President, Medicines Discovery and Development and as a member of the company’s Corporate Executive Team on 1 July 2010. As part of his expanded role, Patrick is responsible for ensuring that GSK maintains a flow of potential new medicines through the R&D pipeline from early discovery through to launch.
Patrick joined GSK in May 2006 as Head of Drug Discovery. He has since transformed GSK’s discovery engine to focus on therapy areas that are underpinned by the most promising and mature science, and which offer fresh insights into diseases. Patrick has also spent the past three years re-personalizing Drug Discovery by setting up small, empowered teams – called Discovery Performance Units - to drive success in the pipeline. In 2009 this new approach resulted in a number of potential new medicines progressing into late-stage development.
Prior to joining GSK Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years’ experience of clinical medicine – general internal medicine, cardiovascular medicine and clinical pharmacology – and has an international reputation as a vascular biologist and clinician scientist. His research has been translational, spanning structural and molecular studies, in vitro and in vivo experimental pharmacology and clinical studies including the use of large scale patient databases. He was elected to the Academy of Medical Sciences in 1999 and subsequently became its Registrar before leaving to join GSK.
Back To Top
Last Updated On 09 February 2011